Anticoagulation and Extracorporeal Circuits: The Role of Prostacyclin

  • M. J. Weston
Part of the Current Concepts in Critical Care book series (CRITICAL CARE)

Abstract

That the application of advanced technology in the intensive care unit is in the patient’s best interests is too often taken for granted by those unfamiliar with its use and unwary of possible harmful effects of such technology. For example, the pioneers of haemodialysis recall how the technique was nearly abandoned because it often caused hypotension. This was shown to be due to hypovolemia from unrecognized ultrafiltration and once understood, haemodialysis gradually became an accepted technique for the treatment of acute renal failure and later for chronic renal failure, although more subtle unwanted effects such as complement activation with pulmonary dysfunction and the effects of acetate in the dialysate on the heart have continued to emerge from time to time.

Keywords

Filtration Glycine Heparin Syringe Malaria 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Gimson AES, Hughes RD, Mellon PJ, Woods HF, Langley PG, Canalese J, Williams R, Weston MJ (1980) Prostacyclin to prevent platelet activation during charcoal haemoperfusion in fulminant hepatic failure. Lancet I: 173–175CrossRefGoogle Scholar
  2. Keogh AM, Rylance PB, Weston MJ, Parsons V (1984) Prostacyclin (epoprostenol) haemodialysis in patients at risk of haemorrhage. Proc Eur Dial Transplant Nurses Assoc 13: 51–54Google Scholar
  3. Rylance PB, Gordge MP, Ireland H, Lane DA, Weston MJ (1984) Haemodialysis with prostacyclin (epoprostenol) alone. Proc Eur Dial Transplant Assoc Eur Ren Assoc 21: 281–286Google Scholar
  4. Salzman EW (1986) Low-molecular-weight heparin. Is small beautiful? N Engl J Med 315: 957–959PubMedCrossRefGoogle Scholar
  5. Turney JH, Williams LC, Fewell MR, Parsons V, Weston MJ (1980) Platelet protection and heparin sparing with prostacyclin during regular dialysis therapy. Lancet II: 219–222CrossRefGoogle Scholar
  6. Turney JH, Woods HF, Fewell MR, Weston MJ (1981) Factor VIII complex in uraemia and effects of haemodialysis. Br Med J 282: 1653–1656CrossRefGoogle Scholar
  7. Weston MJ (1978) Platelet function in fulminant hepatic failure and effects of charcoal haemoperfusion. MD Thesis, Cambridge UniversityGoogle Scholar
  8. Weston MJ (1983) Prostacyclin and extracorporeal circulation. Br Med Bull 39: 285–288PubMedGoogle Scholar
  9. Weston MJ, Hanid MA, Rubin MH, Langley PG, Mellon PJ, Williams R (1977a) Biocompatibility of coated and uncoated charcoal during haemoperfusion in healthy dogs. Eur J Clin Invest 7: 401–406PubMedCrossRefGoogle Scholar
  10. Weston MJ, Langley PG, Rubin MH, Hanid MA, Mellon PJ, Williams R (1977b) Platelet function in fulminant hepatic failure and effect of charcoal haemoperfusion. Gut 18: 897–902PubMedCrossRefGoogle Scholar
  11. Woods HF, Ash G, Weston MJ, Bunting S, Moncada S, Vane JR (1978) Prostacyclin can replace heparin in haemodialysis in dogs. Lancet II: 1075–1077CrossRefGoogle Scholar
  12. Woods HF, Weston MJ, Bunting S, Moncada S, Vane JR (1980) Prostacyclin eliminates the thrombocytopenia associated with charcoal haemoperfusion and heparin and fibrin consumption. Int J Artif Organs 3: 127–132Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • M. J. Weston

There are no affiliations available

Personalised recommendations